MedTrace Logo

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

NCT01945762 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2024-12-18

No results posted yet for this study

Summary

This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative and RET positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic MTC.

Conditions

  • Symptomatic, Aggressive, Sporadic, Unresectable, Locally
  • Advanced/Metastatic Medullary Thyroid Cancer (MTC)

Interventions

DRUG

Vandetanib 300 mg

Vandetanib commercial tablets

Sponsors & Collaborators

  • Worldwide Clinical Trials

    collaborator OTHER

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-17
Primary Completion
2020-06-18
Completion
2020-06-18

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Luxembourg
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01945762 on ClinicalTrials.gov